-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明，無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Benitec Biopharma (NASDAQ:BNTC) Versus BridgeBio Pharma (NASDAQ:BBIO) Critical Analysis
Benitec Biopharma (NASDAQ:BNTC) Versus BridgeBio Pharma (NASDAQ:BBIO) Critical Analysis
BridgeBio Pharma (NASDAQ:BBIO – Get Rating) and Benitec Biopharma (NASDAQ:BNTC – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, dividends, earnings and risk.
Analyst Recommendations
This is a breakdown of recent ratings and recommmendations for BridgeBio Pharma and Benitec Biopharma, as provided by MarketBeat.com.
Get BridgeBio Pharma alerts:| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BridgeBio Pharma | 0 | 0 | 5 | 0 | 3.00 |
| Benitec Biopharma | 0 | 0 | 2 | 0 | 3.00 |
BridgeBio Pharma currently has a consensus target price of $23.00, indicating a potential upside of 172.84%. Benitec Biopharma has a consensus target price of $4.00, indicating a potential upside of 1,613.80%. Given Benitec Biopharma's higher probable upside, analysts clearly believe Benitec Biopharma is more favorable than BridgeBio Pharma.
Earnings and Valuation
This table compares BridgeBio Pharma and Benitec Biopharma's revenue, earnings per share and valuation.| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BridgeBio Pharma | $69.72 million | 18.07 | -$562.54 million | ($3.36) | -2.51 |
| Benitec Biopharma | $70,000.00 | 93.30 | -$18.21 million | ($119.48) | 0.00 |
Benitec Biopharma has lower revenue, but higher earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Benitec Biopharma, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares BridgeBio Pharma and Benitec Biopharma's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| BridgeBio Pharma | -553.52% | N/A | -67.43% |
| Benitec Biopharma | N/A | -203.69% | -151.61% |
Risk and Volatility
BridgeBio Pharma has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500. Comparatively, Benitec Biopharma has a beta of 1.22, suggesting that its share price is 22% more volatile than the S&P 500.
Institutional and Insider Ownership
96.5% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 69.7% of Benitec Biopharma shares are held by institutional investors. 29.6% of BridgeBio Pharma shares are held by company insiders. Comparatively, 1.6% of Benitec Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Summary
BridgeBio Pharma beats Benitec Biopharma on 7 of the 13 factors compared between the two stocks.
About BridgeBio Pharma
(Get Rating)
BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.
About Benitec Biopharma
(Get Rating)
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.
Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
BridgeBio Pharma (NASDAQ:BBIO – Get Rating) and Benitec Biopharma (NASDAQ:BNTC – Get Rating) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, valuation, analyst recommendations, profitability, dividends, earnings and risk.
橋生物醫藥(納斯達克：BBIO-GET評級)和貝尼泰克生物醫藥(納斯達克：BNTC-GET評級)都是小盤醫療公司，但哪一家更好？我們將根據這兩家公司的機構所有權、估值、分析師建議、盈利能力、股息、收益和風險的實力進行比較。
Analyst Recommendations
分析師建議
This is a breakdown of recent ratings and recommmendations for BridgeBio Pharma and Benitec Biopharma, as provided by MarketBeat.com.
這是由MarketBeat.com提供的BridgeBio Pharma和Benitec Biophma最近的評級和推薦細目。
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| BridgeBio Pharma | 0 | 0 | 5 | 0 | 3.00 |
| Benitec Biopharma | 0 | 0 | 2 | 0 | 3.00 |
| 銷售評級 | 保持評級 | 購買評級 | 強勁的買入評級 | 評級分數 | |
| 布里奇比奧製藥 | 0 | 0 | 5 | 0 | 3.00 |
| Benitec Biopma | 0 | 0 | 2 | 0 | 3.00 |
BridgeBio Pharma currently has a consensus target price of $23.00, indicating a potential upside of 172.84%. Benitec Biopharma has a consensus target price of $4.00, indicating a potential upside of 1,613.80%. Given Benitec Biopharma's higher probable upside, analysts clearly believe Benitec Biopharma is more favorable than BridgeBio Pharma.
BridgeBio Pharma目前的共識目標價為2300美元，表明潛在上行空間為172.84%。Benitec Biophma的共識目標價為4.00美元，表明潛在漲幅為1,613.80%。鑑於Benitec Biophma更有可能上行，分析師顯然認為Benitec Biophma比BridgeBio Pharma更有利。
Earnings and Valuation
收益和估值
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| BridgeBio Pharma | $69.72 million | 18.07 | -$562.54 million | ($3.36) | -2.51 |
| Benitec Biopharma | $70,000.00 | 93.30 | -$18.21 million | ($119.48) | 0.00 |
| 總收入 | 價格/銷售額比 | 淨收入 | 每股收益 | 市盈率 | |
| 布里奇比奧製藥 | 6972萬美元 | 18.07 | -5.6254億美元 | ($3.36) | -2.51 |
| Benitec Biopma | $70,000.00 | 93.30 | -1,821萬元 | ($119.48) | 0.00 |
Benitec Biopharma has lower revenue, but higher earnings than BridgeBio Pharma. BridgeBio Pharma is trading at a lower price-to-earnings ratio than Benitec Biopharma, indicating that it is currently the more affordable of the two stocks.
Benitec Biophma的收入低於BridgeBio Pharma，但收益高於BridgeBio Pharma。BridgeBio Pharma的市盈率低於Benitec Biophma，表明它目前是兩隻股票中更負擔得起的一隻。
Profitability
盈利能力
This table compares BridgeBio Pharma and Benitec Biopharma's net margins, return on equity and return on assets.
此表比較了BridgeBio Pharma和Benitec Biophma的淨利潤率、股本回報率和資產回報率。
| Net Margins | Return on Equity | Return on Assets | |
| BridgeBio Pharma | -553.52% | N/A | -67.43% |
| Benitec Biopharma | N/A | -203.69% | -151.61% |
| 淨利潤率 | 股本回報率 | 資產回報率 | |
| 布里奇比奧製藥 | -553.52% | 不適用 | -67.43% |
| Benitec Biopma | 不適用 | -203.69% | -151.61% |
Risk and Volatility
風險和波動性
BridgeBio Pharma has a beta of 0.62, suggesting that its share price is 38% less volatile than the S&P 500. Comparatively, Benitec Biopharma has a beta of 1.22, suggesting that its share price is 22% more volatile than the S&P 500.
BridgeBio Pharma的貝塔係數為0.62，這表明其股價的波動性比標準普爾500指數低38%。相比之下，Benitec Biophma的貝塔係數為1.22，這表明其股價的波動性比標準普爾500指數高22%。
Institutional and Insider Ownership
機構和內部人持股
96.5% of BridgeBio Pharma shares are held by institutional investors. Comparatively, 69.7% of Benitec Biopharma shares are held by institutional investors. 29.6% of BridgeBio Pharma shares are held by company insiders. Comparatively, 1.6% of Benitec Biopharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
BridgeBio Pharma 96.5%的股份由機構投資者持有。相比之下，Benitec Biophma 69.7%的股份由機構投資者持有。BridgeBio Pharma 29.6%的股份由公司內部人士持有。相比之下，Benitec Biophma 1.6%的股份由公司內部人士持有。強大的機構持股表明，捐贈基金、對衝基金和大型基金管理公司相信，一隻股票有望實現長期增長。
Summary
摘要
BridgeBio Pharma beats Benitec Biopharma on 7 of the 13 factors compared between the two stocks.
BridgeBio Pharma在兩隻股票比較的13個因素中有7個擊敗了Benitec Biophma。
About BridgeBio Pharma
關於BridgeBio Pharma
(Get Rating)
(獲取評級)
BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development. The company was founded by Charles Homcy, Frank McCormick, Philip Reilly, and Neil Kumar in 2015 and is headquartered in Palo Alto, CA.
BridgeBio Pharma，Inc.致力於識別和推進治療孟德爾疾病患者的變革性藥物。該公司正在進行的開發項目包括從早期發現到後期開發的候選產品。該公司由Charles Homcy、Frank McCormick、Philip Reilly和Neil Kumar於2015年創立，總部位於加利福尼亞州帕洛阿爾託。
About Benitec Biopharma
關於Benitec Biophma
(Get Rating)
(獲取評級)
Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.
Benitec Biophma Inc.是一家處於發展階段的生物技術公司，專注於新型基因藥物的開發。該公司開發基於DNA指導的RNA幹擾的療法，用於治療慢性和威脅生命的人類疾病。該公司正在開發BB-301，一種基於腺相關病毒的基因治療劑，用於治療眼嚥肌營養不良症。該公司成立於1995年，總部設在加利福尼亞州海沃德。
Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
獲得BridgeBio Pharma Daily的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收BridgeBio Pharma和相關公司的最新新聞和分析師評級的每日摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國，moomoo上的投資產品和服務由Moomoo Financial Inc.提供，一家受美國證券交易委員會（SEC）監管的持牌主體。 Moomoo Financial Inc.是金融業監管局（FINRA）和證券投資者保護公司（SIPC）的成員。
在新加坡，moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供，該公司受新加坡金融管理局（MAS）監管(牌照號碼︰CMS101000) ，持有資本市場服務牌照 (CMS) ，持有財務顧問豁免（Exempt Financial Adviser）資質。本內容未經新加坡金融管理局的審查。
在澳大利亞，moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供，該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構（AFSL No. 224663）。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件，這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大，透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供，並受加拿大投資監管機構（CIRO）監管。
在馬來西亞，moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供，該公司受馬來西亞證券監督委員會（SC）監管(牌照號碼︰eCMSL/A0397/2024) ，持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.，Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧